What We Do
What We Do
Develop Novel Cancer Drugs
OBI Pharma Inc. (OBI) is dedicated to developing novel cancer therapeutic agents for patients with unmet medical needs. We aim to develop therapeutics that improve patient’s health and quality of life.
Our Expertise in Glycoscience
Since 2002, we pioneered our first modality: a glycan antigen-targeted cancer vaccine. Drawing from years of experience in glycoscience, we've elevated our technology to establish OBI’s proprietary glycan-based ADC platforms.
Intellectual Property
+
Patent filed
In US, Europe, Asia, and more
Indication Studied
+
Indications
Broad coverage to unmet medical needs
Worldwide Clinical Studies
+
Sites
Ongoing clinical studies across 13+ countries